ReviewActa pharmaceutica Sinica. B2014
Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.
Review in Acta pharmaceutica Sinica. B, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Ionic Liquid Pilocarpine Serves as Therapeutic Cosolvent and Permeation Enhancer for Glaucoma Medication.ACS pharmacology & translational science · 2026Article
- Article
- Insights into the Recent Breakthroughs in Nanotechnological Outlook of Pentacyclic Triterpenoids: An Updated Approach.Current pharmaceutical design · 2026Review
- Physics-Based Solubility Prediction for Organic Molecules.Chemical reviews · 2025Review
- Unveiling the anticancer potential of Curcuma amada rhizome extract against prostate cancer through computational and experimental approaches.Scientific reports · 2025Article
- Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction.Nucleic acids research · 2024Article
- Accelerating Drug Product Development and Approval: Early Development and Evaluation.Pharmaceutical research · 2024Article
- Is it enough just to demonstrate that the advanced therapy medicinal products do work or we would prefer to keep walking on the Moon?Regenerative therapy · 2023Article
- Local pharmaceutical research and development capacity in a developing country: a qualitative exploration of perspectives from key stakeholders in Ethiopia.Journal of pharmaceutical policy and practice · 2022Article
- Effects of Solvents, Emulsions, Cosolvents, and Complexions on Ex Vivo Mouse Myometrial Contractility.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Resveratrol Nanocrystal Incorporated into Mesoporous Material: Rational Design and Screening through Quality-by-Design Approach.Nanomaterials (Basel, Switzerland) · 2022Article
- New Antifungal Compound: Impact of Cosolvency, Micellization and Complexation on Solubility and Permeability Processes.Pharmaceutics · 2021Article
- Potential Enhancement of Metformin Hydrochloride in Lipid Vesicles Targeting Therapeutic Efficacy in Diabetic Treatment.International journal of molecular sciences · 2021Article
- Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.Current research in pharmacology and drug discovery · 2021Review
- Therapeutic Potential of Thymoquinone and Its Nanoformulations in Pulmonary Injury: A Comprehensive Review.International journal of nanomedicine · 2021Review
- Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.Frontiers in chemistry · 2021Review
- Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.The AAPS journal · 2020Article
- Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches.Pharmaceutics · 2020Review
- Overcoming chemotherapy resistanceActa pharmaceutica Sinica. B · 2019Article
- Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is common these years. The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties, lack of efficacy and safety reasons. Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability. The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.